Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
4th of May 2021: Annual General Meeting
The 2020 Annual General Meeting of Gentian Diagnostics AS will be held on 4th May 2020 at 10:00 (CEST) at Bjørnåsveien 5, 1596 Moss.
Please find the notice incl. appendices enclosed here:
- 4th May 2021 - AGM Minutes GD AS
- Notice of Annual General Meeting for Gentian Diagnostics AS 04.05.2021
- 2020 Annual Report Gentian Diagnostics AS
- 2021 Proposal from Nomination Committee
Financial Calendar 2021
11TH FEB - QUARTERLY REPORT- Q4
16TH APR - ANNUAL REPORT
16TH APR - QUARTERLY REPORT - Q1
4TH MAY - ANNUAL GENERAL MEETING
25TH AUG - HALF-YEARLY REPORT
- 25th August 2021 - Half-Yearly Report
- 25th August 2021 - Half-Yearly Presentation
21ST OCT - QUARTERLY REPORT - Q3
- 21st October 2021 - Quarterly Report - Q3
- 21st October 2021 - Quarterly Presentation - Q3